Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Coherus Oncology, Inc. (CHRS)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M | $475.8M | $356.1M | $0 | $1.6M | $189.5M | $30.0M | $31.1M | $2.8M | $1.9M |
| Research & development | $108.9M | $91.8M | $109.4M | $199.4M | $363.1M | $142.8M | $94.2M | $110.2M | $162.4M | $254.4M | $213.1M | $78.2M | $31.3M | $34.9M |
| Operating expenses | — | — | — | — | — | — | $248.3M | $204.4M | $233.7M | $306.0M | $249.1M | $95.8M | $38.7M | $40.4M |
| Operating income | −$181.1M | −$199.7M | −$203.2M | −$256.9M | −$263.9M | $156.3M | $107.8M | −$204.4M | −$232.1M | −$115.9M | −$219.1M | −$64.7M | −$36.0M | −$38.5M |
| EBITDAderived | −$179.8M | −$198.1M | −$200.0M | −$253.3M | −$260.4M | $159.2M | $111.0M | −$201.2M | −$228.7M | −$112.9M | −$217.2M | −$64.0M | −$35.6M | −$38.3M |
| Net income | $168.0M | $28.5M | −$237.9M | −$291.8M | −$287.1M | $132.2M | $89.8M | −$209.3M | −$238.2M | −$127.3M | −$223.3M | −$87.1M | −$53.6M | −$33.0M |
| Basic EPSper diluted share | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.85 | $1.29 | -$3.22 | -$4.48 | -$3.04 | -$6.01 | -$10.64 | -$16.10 | -$15.85 |
| Diluted EPSper diluted share | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.62 | $1.23 | -$3.22 | -$4.48 | -$3.04 | -$6.01 | -$10.64 | -$16.10 | -$15.85 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 23, 2025Form 4 | Wahlstrom MatsDirector | SellCommon Stock · indirect | 100.0K | $0.74 | $74.0K | 0 |